Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandeep Dutta

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
The AAPS Journal|December 12, 2012
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patientsDag Nyholm, Per Odin, Anders Johansson, et al.
Clinical Pharmacology in Drug Development|May 3, 2017
Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human StudyChih-Wei Lin, Sandeep Dutta, Armen Asatryan, et al.
Journal of Clinical Pharmacology|May 25, 2010
Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteersAhmed A Othman, Robert A Lenz, Jun Zhang, et al.
Epilepsy Research|February 11, 2003
Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsyJames C Cloyd, Sandeep Dutta, Guoliang Cao, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without DasabuvirAkshanth R Polepally, Sandeep Dutta, Beibei Hu, et al.
Epilepsy Research|April 12, 2002
Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteersSandeep Dutta, Yiming Zhang, Daniel S Selness, et al.
Clinical Pharmacokinetics|April 18, 2023
Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the ProteasomeMarc R Yago, Khamir Mehta, Maitreyee Bose, et al.
Clinical Pharmacokinetics|April 16, 2015
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safetyAhmed A Othman, Krai Chatamra, Mohamed-Eslam F Mohamed, et al.
Clinical Pharmacokinetics|September 3, 2015
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyPrajakta S Badri, Jennifer R King, Akshanth R Polepally, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 20, 2021
Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian SubjectsAshit Trivedi, Fady I Malik, Mia Mackowski, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
The AAPS Journal|December 12, 2012
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patientsDag Nyholm, Per Odin, Anders Johansson, et al.
Clinical Pharmacology in Drug Development|May 3, 2017
Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Doses of Pibrentasvir in a First-in-Human StudyChih-Wei Lin, Sandeep Dutta, Armen Asatryan, et al.
Journal of Clinical Pharmacology|May 25, 2010
Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteersAhmed A Othman, Robert A Lenz, Jun Zhang, et al.
Epilepsy Research|February 11, 2003
Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsyJames C Cloyd, Sandeep Dutta, Guoliang Cao, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without DasabuvirAkshanth R Polepally, Sandeep Dutta, Beibei Hu, et al.
Epilepsy Research|April 12, 2002
Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteersSandeep Dutta, Yiming Zhang, Daniel S Selness, et al.
Clinical Pharmacokinetics|April 18, 2023
Mechanistic Pharmacokinetic/Pharmacodynamic Modeling in Support of a Patient-Convenient, Longer Dosing Interval for Carfilzomib, a Covalent Inhibitor of the ProteasomeMarc R Yago, Khamir Mehta, Maitreyee Bose, et al.
Clinical Pharmacokinetics|April 16, 2015
Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safetyAhmed A Othman, Krai Chatamra, Mohamed-Eslam F Mohamed, et al.
Clinical Pharmacokinetics|September 3, 2015
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyPrajakta S Badri, Jennifer R King, Akshanth R Polepally, et al.
European Journal of Drug Metabolism and Pharmacokinetics|August 20, 2021
Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian SubjectsAshit Trivedi, Fady I Malik, Mia Mackowski, et al.
Pageof 12